ETHICAL REVIEW COMMITTEE, ICDDR, B.

Application No.    Circle the Study   Continuation with change   Continuation with change   No change (do not fill out rest of form)	Pri	ncipa	I Investigator $\frac{\sum_{M} \widehat{A}}{A}$	4.197		rain	nee Investigator (if any)
Title of Study Fifth Advantage Project status:    New Study   New	App	licat	ion No. $84-018$		S	uppo	rting Agency (if Non-ICDDR.B) (NI)
Circle the appropriate answer to each of the following (if Not Applicable write NA).  1. Source of Population: (a) Ill subjects Yes No (b) Non-ill subjects Yes No (c) Minors or persons under guardianship 2. Does the study involve: (a) Physical risks to the subjects Yes No (b) Social Risks (c) Psychological risks to subjects Yes No (d) Discomfort to subjects Yes No (e) Invasion of privacy (f) Disclosure of information damaging to subject or others 3. Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (c) Use of organs or body fluids 4. Are subjects Clearly informed about: (a) Nature and purposes of study (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or to withdraw (Required) (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (f) Gonfidential handling of data (f) Right to refuse to participate or to withdraw (Reguired) (f) Right to refuse to participate or to withdraw (Reguired) (g) Confidential handling of data (g) Confidential handling of data (g) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No  Ne agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.	Tit	le of	Study Effect of A	More.			
Circle the Appropriate answer to each of the following (If Not Applicable write NA).  Source of Population:  (a) Ill subjects (b) Non-ill subjects (c) Minors or persons under guardianship 2. Does the study involve: (a) Physical risks to the subjects (d) Discomfort to subjects (d) Discomfort to subjects (e) Psychological risks to subjects (d) Discomfort to subjects Ves No (e) Invasion of privacy (f) Disclosure of information damaging to subject or others 3. Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (a) Nature and purposes of study (c) Use of organs or body fluids 4. Are subjects clearly informed about: (a) Nature and purposes of study (c) Physical risks (d) Procedures to be followed including alternatives used (e) Benefits to be derived (f) Right to refuse to participate or to with-draw from study (d) Confidential handling of data (e) Compensation 8/or treatment where there are risks or privacy is involved in any particular procedure Yes No  Ne agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.  Continuation with change (fol ont fill out rest of form)  No change (do not fill out rest of form)  No change (do not fill out rest of form)  No hill signed consent form be required:  (a) From subjects  Yes No  (b) From parent or guardian  (f) Subjects are minors) Yes No  Chek documents being submitted herewith overview (all other requirements will be submitted with individual studies overview (all other requirements will be submitted with individual studies overview (all other requirements will be submitted with individual studies overview (all other requirements will be submitted with individual studies overview (all other requirements will be submitted with individual studies overview (all other requirements will be submitted with individual studies overview (all other requirements will be submitted with individual studies overview (all other requ	Ο,	nter	, <u>, , , , , , , , , , , , , , , , , , </u>	` -			
Circle the appropriate answer to each of the following (If Not Applicable write NA).  1. Source of Population:  (a) Ill subjects (b) Non-ill subjects (c) Minors or persons under guardianship under guardianship (a) Physical risks (b) Social Risks (c) Psychological risks (d) Discomfort to subjects Vés No (e) Invasion of privacy (f) Disclosure of information damaging to subject or others (a) Use of records, (hospital, medical, death, birth or other) (c) Use of organs or body fluids (a) Nature and purposes of study (a) Nature and purposes of study (d) Sensitive questions (e) Procedures to be followed including alternative sused Yes No (d) Sensitive questions (e) Repfits to be derived Yes No (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (g) Compensation 4/or treatment where there are risks or privacy is involved in any particular procedure Yes No  No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.	<del> </del>		4 4		WAYN (	)	Continuation with change
(a) Ill subjects (b) Non-ill subjects (c) Minors or persons under guardianship 2. Does the study involve: (a) Physical risks (b) Social Risks (c) Psychological risks (d) Discomfort to subjects (d) Discomfort to subjects (e) Invasion of privacy (f) Disclosure of information damaging to subject or others 3. Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids 4. Are subjects clearly informed about: (a) Nature and purposes of study (b) Prom parent or guardian (if subjects are minors) Yes No (if subjects are minors) (if plication are minor and anymity of subjects are minors) (if check documention i		· · · /			(	•	
(a) Ill subjects Yes No (b) Non-ill subjects Yes No (c) Minors or persons under guardianship 2. Does the study involve: (a) Physical risks to the subjects Yes No (b) Social Risks (c) Psychological risks to subjects Yes No (d) Discomfort to subjects Yes No (e) Invasion of privacy (f) Disclosure of information damaging to subject or others 3. Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids 4. Are subjects clearly informed about: (a) Nature and purposes of study (b) Prom parent or guardian (if subjects are minors) Yes No (c) Mult precautions be taken to protect anonymity of subjects anonymity of subjects anonymity of subjects are minors) Yes No (d) Discomfort to subjects Yes No (e) Invasion of privacy (f) Disclosure of information damaging to subject or others 3. Does the study involve: (a) Wes of records, (hospital, medical, death, birth or other) (b) Use of organs or body fluids 4. Are subjects Yes No (c) Use of organs or body fluids 4. Are subjects (learly informed about: (a) Nature and purposes of study (b) Prom parent or guardian (lif subjects are minors) Yes No (mittee:  Ubbrella proposal - Initially submit overview (all other requirements will be submitted with individual studies Protectol (Required)  Abstract Summary (Required)  Informed consent form for parent or guardian  Procedure for subjects  No (b) Use of organs or body fluids  Yes No (c) Use of organs or body fluids  4. Are subjects are minors) Yes No No No (c) Use of records, (hospital, medical, death, birth or other) (g) Prom subjects are minors)  Yes No No No (c) Use of organs or subjects are usumited with individual studies overview (all other requirements will overview (all other requirements will be submitted with individual studies Informed consent form for subjects are not subjects on the subje	Cir	clef	chillen chillen		- C - 1		
(a) Ill subjects (b) Non-ill subjects (c) Minors or persons under guardianship 2. Does the study involve: (a) Physical risks (b) Social Risks (c) Psychological risks (d) Discomfort to subjects Ves No (e) Invasion of privacy (f) Disclosure of information damaging to subject or others (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (a) Use of records, (hospital) medical, death, birth or other) (c) Use of organs or body fluids (a) Mature and purposes of study (b) Procedures to be followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or twithdraw from study (g) Confidential handling of data  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.	1.	Sour	ce of Population:	ı eacn	OX TN	e ro	llowing (If Not Applicable write NA).
(b) Non-ill subjects (c) Minors or persons under guardianship 2. Does the study involve: (a) Physical risks to the subjects (b) Social Risks (c) Psychological risks to subjects (d) Discomfort to subjects Ves No (e) Invasion of privacy (f) Disclosure of information damaging to subject or others 3. Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids 4. Are subjects clearly informed about: (a) Nature and purposes of study (b) Procedures to be followed including alternatives used (c) Physical risks (c) Physical risks (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.				Vac	No	э.	
c) Minors or persons under guardianship Yes No and guardianship Yes No 6. Physical risks to the subjects Yes No. (c) Physical risks Yes No. (d) Discomfort to subjects Yes No. (e) Invasion of privacy Yes No. (e) Invasion of privacy Yes No. (f) Disclosure of information damaging to subject or others Yes No. (a) Use of records, (hospital, medical, death, birth or other)  (b) Use of fetal tissue or abortus (a) Nature and purposes of study Yes No. (b) Procedures to be followed including alternatives used Yes No. (c) Physical risks Yes No. (d) Sensitive questions Yes No. (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study Yes No. (e) Gonfidential handling of data  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.							
under guardianship  2. Does the study involve: (a) Physical risks to the subjects (b) Social Risks (c) Psychological risks to subjects (d) Discomfort to subjects (e) Invasion of privacy (f) Disclosure of information damaging to subject or others (a) Use of records, (hospital medical, death, birth or other) (b) Use of fetal tissue or abortus (a) Nature and purposes of study (b) Procedures to be followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation &/or treatment where there are risks or privacy is involved in any participate or to withdraw for treatment where there are risks or privacy is involved in any participate or to withdraw where there are risks or privacy is involved in any participate or to withdraw for the areas to be for review.  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.					110		
2. Does the study involve:  (a) Physical risks to the subjects  (b) Social Risks  (c) Physical risks  (d) Discomfort to subjects  (e) Invasion of privacy  (f) Disclosure of information damaging to subject or others  3. Does the study involve:  (a) Use of records, (hospital, medical, death, birth or other)  (b) Use of fetal tissue or abortus  (c) Use of organs or body fluids  4. Are subjects clearly informed about:  (a) Nature and purposes of study  (b) Procedures to be followed including alternatives used  (c) Physical risks  (d) Sensitive questions  (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study  (g) Confidential handling of data  (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure for any changes involving the rights and welfare of subjects before making such change.		• •			No	6	
(a) Physical risks to the subjects (b) Social Risks (res No Social Risks) (res No Social Risks (res No Social Risks) (res No Social Risks (res No Social Risks (res No Social Ris	2.	Does		, 00		٠.	
subjects (b) Social Risks Yes No (c) Psychological risks to subjects (d) Discomfort to subjects Ves No (e) Invasion of privacy (f) Discolosure of information danaging to subject or others ject or others 3. Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (a) Nature and purposes of study (a) Nature and purposes of study (b) Procedures to be followed including alternatives used (c) Pysical risks (d) Sensitive questions (e) Benefits to be derived Yes No (g) Confidential handling of data (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure of subjects before making such change.  Committee: Umbrella proposal - Initially submit overview (all other requirements will be submitted with individual studies Protocol (Required) Abstract Summary (Required) Statement given or read to subjects informed consent form for subjects Informed consent form for subjects Informed consent form for parent or guardian Procedure for maintaining confidentiity Questionnaire or interview schedule *If the final instrument is not complete prior to review, the following informat should be included in the abstract summ or interview which could be considered either sensitive or which would constitute an invasion of privacy.  Examples of the type of specific questions to be asked in the sensit areas.  An indication as to when the questionaire will be presented to the Ctte for review.						7	
(b) Social Risks (c) Psychological risks to subjects (d) Discomfort to subjects Ves (e) Invasion of privacy (f) Disclosure of information damaging to subject or others 3. Does the study involve: (a) Use of records, (hospital, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids 4. Are subjects clearly informed about: (a) Nature and purposes of study (d) Sensitive questions (e) Benefits to be derived Yes (f) Right to refuse to participate or to withdraw frequired into overview (all other requirements will be submitted with individual studies  Protocol (Required) Abstract Summary (Required) Informed consent form for subjects Informed consent form for parent or guardian Procedure for maintaining confidential instrument is not complete prior to review, the following information of the abstract summary (Questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.  2. Examples of the type of specific questions to be asked in the sensitian areas.  3. An indication as to when the question naire will be presented to the Ctte for review.  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.				Yes	No:	• •	
cc) Psychological risks to subjects to danaging to subject or others the study involve:  (a) Use of records, (hospital, medical, death, birth or other)  (b) Use of fetal tissue or abortus  (c) Use of organs or body fluids  4. Are subjects clearly informed about: (a) Nature and purposes of study  (b) Procedures to be followed including alternatives used to participate or to withdraw (Required)  (c) Physical risks  (d) Sensitive questions  (e) Benefits to be derived (e) Benefits to be derived for mitter to review, the following informat should be included in the abstract summary (Required)  Abstract Summary (Required)  Abstract Summary (Required)  Abstract Summary (Required)  Statement given or read to subjects to participate or withdraw (Required informed consent form for subjects informed in subjects in subjects informed in subjects informed in subje		(b)	Social Risks				Umbrella proposal - Initially submit
to subjects  (d) Discomfort to subjects Yes No (e) Invasion of privacy (f) Disclosure of information damaging to subject or others  Jest of records, (hospital, medical, death, birth or other)  (b) Use of fetal tissue or abortus  (c) Use of organs or body fluids  4. Are subjects clearly informed about: (a) Nature and purposes of study (b) Procedures to be followed including alternatives used (c) Physical risks (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or to withdraw Yes No (g) Confidential handling of data (h) Compensation 6/or treatment where there are risks or privacy is involved in any particular procedure  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		(c)	Psychological risks				overview (all other requirements wil
(d) Discomfort to subjects Ves No (e) Invasion of privacy Yes No (f) Disclosure of information damaging to subject or others 3. Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids 4. Are subjects clearly informed about: (a) Nature and purposes of study (b) Procedures to be followed including alternatives used Yes No (c) Physical risks (d) Sensitive questions Yes No (e) Benefits to be derived Yes No (f) Right to refuse to participate or to withdraw (Required)  Abstract Summary (Required)  Informed consent form for parent or guardian  Procedure for maintaining confidential ity  Questionnaire or interview schedule  *If the final instrument is not complete prior to review, the following informat should be included in the abstract summary and particular procedure for maintaining confidential ity  Questionnaire or interview complete prior to review, the following informated should be included in the abstract summary should be considered e			to subjects	Yes	No		be submitted with individual studies
(e) Invasion of privacy (f) Disclosure of information damaging to subject or others  3. Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus  4. Are subjects clearly informed about: (a) Nature and purposes of study (b) Procedures to be followed including alternatives used Yes No (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or withdraw (Required)  Nature and purposes of study, Yes No (d) Sensitive questions Yes No (e) Benefits to be derived (f) Right to refuse to participate or to withdraw (Required)  Nove to aparticipate or withdraw (Required)  Informed consent form for subjects Informed consent form for parent or guardian  Procedure for maintaining confidentiation in the following information to private to participate or withdraw (Required)  Informed consent form for subjects Informed consent form for parent or guardian  Procedure for maintaining confidentiation in the following information to private to participate or withdraw (Required)  Informed consent form for subjects Informed consent form for subjects Informed consent form for parent or guardian  Procedure for maintaining confidentiation in the abstract summation of the areas to be covered in the questionnaire or interview which could be included in the abstract summation of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.  Examples of the type of specific questions to be asked, and right to refuse to participate or withdraw (Required)  Informed consent form for parent or guardian  Procedure for maintaining confidentiation in the abstract summation of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.  Examples of the type of specific questions to be asked in the sensit areas.  An indication as to when the question areas.  An in		(d)	Discomfort to subjects	<b>V</b> Yes	No		
Statement given or read to subjects nature of study, risks, types of que ions to be asked, and right to refuse to participate or withdraw (Required Informed consent form for subjects Informed consent form for subjects Informed consent form for parent or guardian procedure for maintaining confidential ity Questionnaire or interview schedule prior to review, the following informat should be included in the abstract summ should be included in the abstract summ of alternatives used Yes No (d) Sensitive questions Yes No (e) Benefits to be derived Yes No (f) Right to refuse to participate or withdraw from study Yes No (h) Compensation &for treatment where there are risks or privacy is involved in any particular procedure Yes No We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		(e)		Yes	No 1/		
nature of study, risks, types of que ions to be asked, and right to refuse to participate or withdraw (Required Informed consent form for subjects Informed consent form for parent or guardian procedure for maintaining confidentiating and purposes of study for the followed including alternatives used followed including alternatives used followed including alternatives used followed form for subjects learly informed about:  (a) Nature and purposes of study for solowed including alternatives used followed including alternatives used followed including alternatives used followed including alternatives used followed including for data for participate or to withdraw from study for participate or to withdraw from study for participate or to withdraw from study followed in the rights and welfare of subjects before making such change.  Informed consent form for subjects Informed consent form for parent or guardian procedure for maintaining confidentiative or withdraw (Required Informed consent form for subjects to participate or withdraw (Required Informed consent form for subjects to participate or mithraw (consent form for subjects to participate or interview schedule prior to review, the following informat should be included in the abstract summ.  1. A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.  2. Examples of the type of specific questions to be asked in the sensitivation areas.  3. An indication as to when the question naire will be presented to the Ctte for review.		(£)			V		
ions to be asked, and right to refus to participate or withdraw (Required consent form for subjects Informed consent form for parent or guardian procedure for maintaining confidentiality.  (c) Use of organs or body fluids  4. Are subjects clearly informed about: (a) Nature and purposes of study (b) Procedures to be followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (e) Benefits to be derived (f) Right to refuse to participate or to withdraw (Required Informed consent form for subjects Informed consent form for parent or guardian  Procedure for maintaining confidentiality Questionnaire or interview schedule prior to review, the following informat should be included in the abstract summ 1. A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.  2. Examples of the type of specific questions to be asked in the sensitiareas.  3. An indication as to when the question naire will be presented to the Ctte for review.  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.			tion damaging to sub-				nature of study, risks, types of que
1. Does the study involve:  (a) Use of records, (hospital, medical, death, birth or other)  (b) Use of fetal tissue or abortus  (c) Use of organs or body fluids  4. Are subjects clearly informed about:  (a) Nature and purposes of study  (b) Procedures to be followed including alternatives used Yes No  (c) Physical risks  (d) Sensitive questions Yes No  (e) Benefits to be derived (f) Right to refuse to participate or to withdraw (Required Informed consent form for parent or guardian  Procedure for maintaining confidentiality  Questionnaire or interview schedule  *If the final instrument is not complete prior to review, the following informat should be included in the abstract summ 1. A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.  2. Examples of the type of specific questions to be asked in the sensitiances.  3. An indication as to when the questionaire will be presented to the Ctte for review.  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.	_	_		Yes	No.		ions to be asked, and right to refus
ital, medical, death, birth or other)  (b) Use of fetal tissue or abortus  (c) Use of organs or body fluids  4. Are subjects clearly informed about:  (a) Nature and purposes of study  (b) Procedures to be followed including alternatives used Yes No  (c) Physical risks  (d) Sensitive questions  (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study  (g) Confidential handling of data  (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure in the guestion subjects before making such change.  Informed consent form for parent or guardian  Procedure for maintaining confidentiaity Questionnaire or interview schedule  *If the final instrument is not complete prior to review, the following informat should be included in the abstract summ 1. A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.  2. Examples of the type of specific questions to be asked in the sensitiances.  3. An indication as to when the question naire will be presented to the Ctte for review.	3.						to participate or withdraw (Required
birth or other)  (b) Use of fetal tissue or abortus  (c) Use of organs or body fluids  4. Are subjects clearly informed about:  (a) Nature and purposes of study  (b) Procedures to be followed including alternatives used Yes No  (c) Physical risks  (d) Sensitive questions  (e) Benefits to be derived Yes No  (f) Right to refuse to participate or to withdraw from study  (g) Confidential handling of data  (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		(a)					Informed consent form for subjects
(b) Use of fetal tissue or abortus  (c) Use of organs or body fluids  4. Are subjects clearly informed about:  (a) Nature and purposes of study  (b) Procedures to be followed including alternatives used alternatives used (c) Physical risks  (d) Sensitive questions  (e) Benefits to be derived Yes No participate or to withdraw from study  (g) Confidential handling of data  (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.  Procedure for maintaining confidenting ity Questionnaire or interview schedule  If the final instrument is not complete, prior to review, the following informat should be included in the abstract summ.  1. A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.  2. Examples of the type of specific questions to be asked in the sensitic areas.  3. An indication as to when the question naire will be presented to the Ctternal for review.			•	1/			Informed consent form for parent or
abortus  (c) Use of organs or body fluids  4. Are subjects clearly informed about: (a) Nature and purposes of study  (b) Procedures to be followed including alternatives used alternatives used (c) Physical risks  (d) Sensitive questions  (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study  (g) Confidential handling of data  (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.				Yes	No		guardian
(c) Use of organs or body fluids  Yes No  4. Are subjects clearly informed about: (a) Nature and purposes of study (b) Procedures to be followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived Yes No (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.  The fithe final instrument is not complete prior to review, the following informat should be included in the abstract summ.  * If the final instrument is not complete prior to review, the following informat should be included in the abstract summ.  * If the final instrument is not complete prior to review, the following informat should be included in the abstract summ.  * A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.  2. Examples of the type of specific questions to be asked in the sensitive areas.  3. An indication as to when the question naire will be presented to the Ctte for review.  * If the final instrument is not complete prior to review, the following informat should be included in the abstract summ.  1. A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.  2. Examples of the type of specific questions to be asked in the sensitive or which would constitute an invasion of privacy.  3. An indication as to when the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy.  5. An indication as to when the questions areas.  6. An indication as to when the for review.		(0)					Procedure for maintaining confidentia
# If the final instrument is not complete prior to review, the following informat should be included in the abstract summ should be considered either sensitive or which would constitute an invasion of privacy.  (d) Sensitive questions Yes No  (e) Benefits to be derived Yes No  (f) Right to refuse to participate or to withdraw from study Yes No  (g) Confidential handling of data Yes No  (h) Compensation %/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		(-)		Yes	No		•
4. Are subjects clearly informed about:  (a) Nature and purposes of study  (b) Procedures to be followed including alternatives used Yes No  (c) Physical risks Yes No  (d) Sensitive questions Yes No  (e) Benefits to be derived Yes No  (f) Right to refuse to participate or to withdraw from study  (g) Confidential handling of data  (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		(c)		.3/			
(a) Nature and purposes of study  (b) Procedures to be followed including alternatives used  (c) Physical risks  (d) Sensitive questions  (e) Benefits to be derived Yes No  (f) Right to refuse to participate or to withdraw from study  (g) Confidential handling of data  (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.	Æ	1-0			No		
study  (b) Procedures to be followed including alternatives used Yes No  (c) Physical risks Yes No  (d) Sensitive questions Yes No  (e) Benefits to be derived Yes No  (f) Right to refuse to participate or to withdraw from study  (g) Confidential handling of data  (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.	4.			d abou	ut:		
(b) Procedures to be followed including alternatives used Yes No either sensitive or which would (c) Physical risks Yes No constitute an invasion of privacy.  (d) Sensitive questions Yes No 2. Examples of the type of specific questions to be asked in the sensitive or which would constitute an invasion of privacy.  (e) Benefits to be derived Yes No questions to be asked in the sensitive or which would constitute an invasion of privacy.  (f) Right to refuse to questions to be asked in the sensitive or which would constitute an invasion of privacy.  (g) Confidential to refuse to questions to be asked in the sensitive or which would constitute an invasion of privacy.  (g) Confidential handling of data Yes No questions to be asked in the sensitive or which would constitute an invasion of privacy.  (g) Confidential handling for review of areas.  (g) Confidential handling for review.  (h) Compensation %/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		(a)		1	N1		
followed including alternatives used Yes No (c) Physical risks Yes No (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		(b)	•	res	NO		
alternatives used Yes No either sensitive or which would  (c) Physical risks Yes No constitute an invasion of privacy.  (d) Sensitive questions Yes No 2. Examples of the type of specific questions to be asked in the sensit areas.  (e) Benefits to be derived Yes No questions to be asked in the sensit areas.  (f) Right to refuse to participate or to withdraw from study Yes No naire will be presented to the Ctte (g) Confidential handling of data Yes No  (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		(0)		_			
(c) Physical risks  Yes No  (d) Sensitive questions  Yes No  (e) Benefits to be derived Yes No  participate or to withdraw from study  (g) Confidential handling  of data  (h) Compensation &/or treatment where there are risks  or privacy is involved in any particular procedure  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.				ja,	No		
(d) Sensitive questions Yes No  (e) Benefits to be derived Yes No  (f) Right to refuse to  participate or to withdraw from study  (g) Confidential handling  of data  (h) Compensation &/or treatment where there are risks  or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		(c)	_				
(e) Benefits to be derived Yes No questions to be asked in the sensition of Right to refuse to areas.  participate or to withdraw from study Yes No naire will be presented to the Ctte (g) Confidential handling of data Yes No  (h) Compensation 6/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.			•				
(f) Right to refuse to  participate or to with- draw from study  (g) Confidential handling of data  (h) Compensation &/or treat- ment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.			•	Yes	NO NO		
participate or to withdraw from study  (g) Confidential handling of data  (h) Compensation &/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.				160	NO		•
draw from study  (g) Confidential handling  of data  (h) Compensation 6/or treatment where there are risks  or privacy is involved in  any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		<b>.</b> - <i>j</i>		/			
(g) Confidential handling for review.  of data Yes No  (h) Compensation 6/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.					No		
of data  Yes No  (h) Compensation 6/or treatment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		(g)		. /			- · · · · · · · · · · · · · · · · · · ·
(h) Compensation &/or treat- ment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.				Yes	No		2012011
ment where there are risks or privacy is involved in any particular procedure Yes No  We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.		(h)	Compensation 6/or treat	-			
we agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.							•
We agree to obtain approval of the Ethical Review Committee for any changes involving the rights and welfare of subjects before making such change.			or privacy is involved	in ,	/		
involving the rights and welfare of subjects before making such change.			any particular procedur	e Yé	s No		
involving the rights and welfare of subjects before making such change.	We	OTER	to obtain annroyal of	he E+	hical	Dovi	ow Committee for any changes
	invo	lvin	g the rights and welfere	ne Et	micai shiecte	nevi . ha	fore making such change
Principal Investigator Trainee Trainee							toto maning such change.
Principal Investigator / Trainee			( lights m 175	10	. nou	9-	
		Pr	incipal Investigator		·		Trainee

19EF W 5/22, JB2 M 726e 1984

ICODR. B 1 18Y

ACC \$ .0. A-033873

CLASS .W 5/20.37,2

SOURCE COS

## SECTION I - RESEARCH PROTOCOL

1. TITLE: Effect of Severe Protein Energy Malnutrition (PEM) On The

Absorption of Macronutrients In

Bangladeshi Children.

2. PRINCIPAL INVESTIGATORS: Dr. Ayesha Molla Dr. A. M. Molla

3. CO-INVESTIGATORS: Dr. Sultana Khanam, Ms. Makhduma

Khatun, A Research Physician and

Mr. N. Majid.

4. CONSULTANT Dr. M. Mujibur Rahaman

5. STARTING DATE May 1984

6. COMPLETION DATE May 1985

7. TOTAL DIRECT COST US \$38,860 (incremental cost \$24368)

8. SCIENTIFIC PROGRAM HEAD: Dr. M. Mujibur Rahaman

This protocol has been approved by the Nutrition Working Program.

Signature of Scientific Program Head:

Date: 12/4/1984

## 9. ABSTRACT SUMMARY

Forty male children aged between 12 to 3 yr with severe protein energy malnutrition without any signs of systemic infection or after successful treatment of systemic infection will be selected both from Children's Nutrition Unit (CNU), Dhaka and ICDDR.B treatment centre and will be studied in the metabolic study ward of ICDDR, B hospital or at the recovery ward of Children under study will be divided Children Nutrition Unit. into two equal groups, Marasmic (classified as wt. for height lpha60% of NCHS standard and without oedema) and kwashiorkor/marasmickwashiorkor (60 to 80% wt. for height and with oedema). Two main diets containing low (30% kcal derived from fat) and high (50% kcal from fat) concentration of fat will be given to each group In addition the patients will recieve all clinical of patients. care and will be treated following a scheme of management for malnourished children as has been established in the Children The quantitative intake of food at the beginning Nutrition Unit. of dietary rehabilitation and at the end of recovery will be The ability of the patients with severe protein energy malnutrition to absorb different macronutrients fat, nitrogen, carbohydrates and calories will be assessed during two phases of the study.

The acceptability and the effect of low and high fat diet on their early rehabilitation will also be studied.

#### SECTION II - RESEARCH PROTOCOL

#### A. INTRODUCTION

## 1. Objectives:

The ultimate goal of this study is to find out how soon a child with severe protein energy malnutrition can be rehabilitated with an available and familiar high energy Bangladeshi diet of known composition.

## 2. Background:

Following international nutrition surveys (WHO 1972) it was suggested that about 85 to 90 million children below the age of five suffer from moderate to severe degree of malnutrition. Similar data was also obtained in the recent Bangladesh Nutrition Survey. According to WHO, protein energy malnutrition can be defined as: "a range of pathological conditions arising from a coincident lack, in varying proportions of protein and energy, occuring most frequently in infants and young children and Two extreme conditions commonly associated with infections." for severe protein energy malnutriiton are kwashiorkor and Several factors, like poverty, poor hygienic marasmus. conditions, infectious diseases specially diarrhoea, various socio-economic factors and maternal ignorance in child rearing practices are responsible for precipitation of severe PEM. Many studies have shown a very close association between malnutrition Recently, in one of the studies conducted and mortality (1,2). in Matlab, a field study area of ICDDR, B it was demonstrated that severely malnourished children (wt. for age 56%) had a risk of death 14 times more than that of their well nourished counterparts (66% wt. for age). It was emphasised that immediate priority should be given in providing nutritional rehabilitation, which will help in reduction of the young children (3). The most important causes of secondary PEM are,

1) reduced intake due to decreased appetite or anorexia

2) diarrhoea and malabsorption leading to unavailability of nutrients to the body and 3) increased rate of catabolism in various infectious diseases. PEM depresses the body's immune function, with reduction of resistance to infection (4). excess supply of nutrients specially protein and calories are essential to cope with the increased need of these nutrients Also, serum level of micronutrients like vitamin A, folic acid, calcium, phosphorus, potassium, magnesium and iron were reported to be low (5-11) in PEM. However, the body can make use of outside supply of macro and micronutrients if they are administered in optimum proportions. Waterlow et al (12) described two main principles for feeding children with severe protein energy malnutrition. According to him, feeding high energy and high protein diets should be introduced gradually in view of the fact that children with severe PEM might not be able to tolerate and assimilate the nutrients in the body and might go into heart failure due to high cardiac input. Based on the same principle, Rees and Brook (13) carried out a trial in children with diarrhoea aged six weeks to 4 years where threee formula feeds e.g. !) a full strength milk 2) 0.18% sodium chloride and 4% dextrose in water till diarrhoea settled, followed by a full strength milk immediately and 3) 0.18% sodium chloride and 4% dextrose solution till diarrhoea settled following gradual introduction of full strength milk. The results did not show any significant difference in the length of their hospital stay and the usual course of recovery. However, it needs to be emphasized that children with acute diarrhoea are different from the children with severe PEM who needs intensive clinical attention as well as carefully selected dietary therapy. According to the second principle of Waterlow et al (12), in order to reduce the danger of hypothermia, hypoglycaemia and to avoid overloading the gut, food should be given in small amounts e.g.

one hourly feeds for the 1st and 2nd days of hospitalization. According to Alleyne et al (14) therapeutic diets in PEM was provided in Uganda and Jamaican children as shown in Table 1. To reduce hypoglycaemia and hypothermia, formula feeds were given frequently through the whole day to achieve 150-200 kcal/kg/day for marasmic and 110 kcal/kg/day for kwashiorkor till the oedema disappears and diuresis was achieved. After that to achieve maximum rate of weight gain increased amount of milk feeds i.e. 150-200 kcal/kg/day were supplied (14).

In Dhaka, Eskaton, a Children Nutrition Unit (CNU) was established in 1975 by UK, Save the Children Fund, where marasmic, marasmic-kwarshiorkor children have been treated successfully with mortality of only 5% of the total admission. In CNU. Dr. Sultana and her co-workers are using a diet regimen which contain local, inexpensive ingredients and is culturally accept able and provides adequate nutrients to satisfy the requirement of the children aged 12 to 5 years. The dietary regimen are presented in the Table 2. The formula for dried skimmed milk (given 2 hourly for 24 hours), rice pudding or suji (given at breakfast at 8 a.m.), rice vegetable and meat mixture (given at 12 noon) or chapati who do not like rice, snack roll (at 3 pm) and dal, rice (given at 6 pm) are given in Table 3. children refuse to eat initially due to anorexia, and other complications and then accept food within a few days. All foods are salt free and offered ad libitum. At the beginning of 2nd week of hospitalization milk feed was reduced to 4 times (6 am, 10 am, 4 pm and 10 pm) with 180 mls of DSM each time. cooked meals were offered 3 times at breakfast, lunch and supper. Egg, banana is given at special circumstances, usually when serum protein is lower than 3 gm% and in case of food refusal. In addition to the solid and milk feed, vitamin A, multivitfolic acid, ferrous sulphate, vitamin K, potassium, magnesium (and blood transfusion when indicated) are given routinely. In

case of clinically suspected iodine deficiency lugols iodine is commonly used. With the above dietary regimen feeding 200 kcal/kg/day in CNU, the children usually achieve maximum catch up growth and weighs up to 80 to 85% of weight for height of the Median Harvard standard. The average hospital stay is up to 4 weeks.

To obtain some besic informations with regard to quantitative intake and absorption of nutrients during the early and late phase of rehabilitation it is essential to formulate a proper nutritional therapy for the children with severe PEM. in the literature informations on absorption of macronutrients in severe PEM are lacking. In our previous studies (15) in children with acute diarrhoea and mild to moderate degree of malnutrition, evidence has shown that in general there is a negative correlation between absorption of nutrients and nutritional status of children. However, absorption of nutrients varied in different aetiology of diarrhoea and also different nutrients were absorbed with varying degrees of efficiency. The detailed findings of these studies are recently published (16-19). With this background information, a new study is designed to investigate the quantitative intake of nutrient and their absorption for evolving a high energy, culturally acceptable and easily available dietary regimen for rapid rehabilitation of children with severe PEM. We intend to carry out the sutdy with two kinds of diet containing lower and higher quantity of fat during rehabilitation and find out if the length of rehabilitation process can be shortened with high fat diet.

#### 3. Rationale:

Severe protein energy malnutrition (PEM) can be regarded as a scourge in the developing countries. Highest mortality was observed in 2 year aged children with severe PEM (3). Specific

information on intake and absorption of nutrients are needed for formulation of an effective dietary regimen for early and rapid nutritional rehabilitation. High energy diet is a key factor for rapid rehabilitation and the concentrated energy can only be provided through fat. Hence, it is essential to find out, to what extent diets with higher fat content are absorbed in children with severe PEM. These informations can be used as a guide for effective dietary therepy of the children with PEM.

## B. SPECIFIC AIMS:

- 1. Estimate the quantitative intake of food and the co-efficients of absorption of nutrients (fat, nitrogen, calories and carbohydrate) in severely malnourished children in the early and later stages of rehabilitation.
- 2. Find out the extent of fat absorption from two diets containing lower (30%) and higher amount of fat (50%).

#### C. METHODS AND PROCEDURES:

Patients: Study patients with severe PEM will be selected both from the Children Nutrition Unit (CNU) and ICDDR, B treatment centre. However, to minimize compounding variables, it would be better if the metabolic study is done in Children Nutrition Unit. In case it is not feasible to carry out the study in CNU, the patients after preliminary investigations should be transferred to ICDDR, B. The classification of malnutrition will be done according to the existing practice of Children Nutrition Unit.

#### Selection Criteria

- i) 40 malnourished male children, aged between 12 year to 3 years and completely weaned from the breast milk will be selected.
- ii) Nutritional status will be determined by weight for height percentage of NCHS standard and presence or

absence of oedema. Patients will be divided into 2 groups, one with 20 children and having 80-60% of standard wt. for ht. with oedema, will be accepted in the kwashiorkor group and the second 20 with ₹60% of standard wt. for ht. and without oedema will be taken in the marasmus group. Each twenty will further be subdivided into two equal groups each group having 10 children. Ten children from both the kwashiorkor or marasmus groups will recieve diet 1 (low fat content) and rest will recieve diet 2 (high fat content). Table 4 presents the criteria for selection. Table 5 and 6 present the low and high fat diets.

iii) Children having acute diarrhoea, liver disease, surgical conditions, injury, tuberculosis, septicaemia or any other severe systemic disease will not be included in the study. Children having urinary tract infection, upper respiratory infection or any other systemic infection with mild manifestations will be first treated by appropriate antibiotics and included into the study after the antibiotic course is over and successful clinical recovery.

#### Procedure

Step I. Initially after admission, during the first 2 days, a thorough physical examination will be done and routine clinical investigations will be carried out. 3-5 mls of venous blood samples will be taken for blood culture, TC, DC, Hct, haemoglobin and total plasma protein. Stool and urine samples will be taken for microscopic examination and bacteriological culture. X-ray chest will be taken if indicated.

Step II. Children with severe PEM most often have associated diarrhoea, vomiting and dehydration. In presence of dehydration, patients should be treated with intravenous fluid routinely as usual in ICDDR, B. Amount and type of fluid to be given should be decided by the treating physician on clinical judgement

and guided by serum electrolyte results. Within 4 to 6 hours of rehydration therapy the children can be fed by mouth if the patients' condition permits.

Step III. If the patients are unable to eat due to ulcers in the mouth, anorexia or extreme debility, the feed will be homogenized into semi-liquid formula and fed through a nasogastric tube till the child is able to eat by mouth. For the first 3 days of hospitalization, feeding schedule will be kept as shown in Table 7.

Step IV. Nearly all malnourished children suffer from deficiency of vitamins and minerals. According to the usual practice of CNU, all children will be given folic acid, riboflavin, ascorbic acid, folfetab (and high potency vitamin A cap) throughout the whole period of rehabilitation.

Step V. Balance Study. After the first three days of hospitalization or at a time when it will be proved that the patient is free from any systemic disease, the balance study will be started . Before that all patients will be fed ad libitum two hourly as shown in Table 7 to provide 100 to 150 kcal/kg/day. The daily allowance of calories, fat and nitrogen per kg of wt. will be decided according to the standard practice in children Seventy-two hour balance study will be carried nutrition unit. out by using markers as previously published (16-19). Feeding schedules during balance study are given in Table 5&6. Quantitative measurements of all intake and output will be recorded. aliquotes of homogenized food and stool will be analysed for the content of nitrogen, fat, carbohydrate and calories according to (20, 21). After the first 72 hour study standard techniques the patients will continue getting the same diets and the progress interms of 'daily weight gain will be recorded. progressive increase in calorie intake will be according to standard practice in Children Nutrition Unit and daily weight

gain will be recorded until the patient goes home i.e. weight for height will be at 85th centile or more. At that time a second 72 hour balance study will be carried out and this study will serve as the control of the previous one. A second blood sample of 2 ml will be taken for monitoring the biochemical improvement of the patient.

Step VI. Screening Tests for Malabsorption. D-xylose test is the only test available to assess generalized malabsorption. This test will be done by feeding 5 gram D-xylose dissolved in 100 ml of water on the day before starting the study. After I hour of drinking D-xylose solution, 0.5 ml of blood sample will be drawn for estimation of serum xylose level (22). Repeat xylose will be done on the day before the second balance study.

## D. STATISTICAL ANALYSIS

- i) Intake of food and nutrients in marasmus and kwashiorkor group between the early and later stage of rehabilitation process will be compared using paired t test.
- ii) Co-efficients of absorption of nutrients in severe protein energy malnutrition will be estimated and compared with the recovery period of rehabilitation.
- iii) Correlation between weight gain and absorption of different nutrients will be done.
  - iv) Ability of the patients to absorb higher amount of dietary fat at different degrees of malnutrition will be estimated and tolerance will be compared between the acute and recovery period of different nutritional status.

#### E. SIGNIFICANCE

For early rehabilitation of severely malnourished children, intake of increased calories is mandatory. Volume of the food often becomes a problem. Hence caloric dense diet will be a substantial help in this regard. Fat provides most calories among all the nutrients. But the ability of children with 3rd degree malnutrition in handling the higher amount of fat (50% of total energy) is not known. This study will provide valuable information in this respect and these informations will contribute significantly in the formulation of a proper dietary therapy for the early rehabilitation of these children.

## F. FACILITIES REQUIRED:

- i) No new office space is required.
- ii) Laboratory facilities for routine microbiology, biochemistry and clinical pathology are adequate.
- iii) Statistical data analysis: Help of Statistical Branch will be utilised. Mini computer HP 85 will be adequate for the purpose of data analysis.
- vi) Hospital Resources: The study will utilise patients selected from the outpatient treatment centre of ICDDR, B and CNU. The balance study will be conducted in the metabolic ward of ICDDR, B or in CNU.

#### REFERENCES

- 1. Somer A, Loewenstein M.S. Nutritional status and mortality: a prospective validation of the quack stick.

  Am J. Clin. Nutr. 1975; 28:287.92.
- 2. Chen L.C., Chowdhury A.K.M.A., Huffman S.L.
  Anthropametric assessment of energy protein among pre-school aged children. Am. J. Clin. Nutr. 1980; 33: 1836-45.
- 3. S.K. Roy, A.K.M.A. Chowdhury, M.M. Rahaman Excess mortality among children discharged from hospital after treatment fordiarrhoea in rural Bangladesh. Br. M.J. 1983; 287: 1097-99
- 4. R.K. Chandra. Immunodeficiency in Undernutrition and Overnutrition. Nutr. Rev. 1981; 39: 225-31.
- 5. Garrow J.S. Total body pottasium in Kwashiorkor Lancel 1967; 11:643-5
- Garrow, J.S., Smith R. and Ward, E.E.
   Electrolyte metabolism in severe infantile malnutrition 1968:
   Pergamon Press: Oxford
- 7. Graham, G.G., Cordano, A. Blizzard, R.M. and Cheek D.B., Infantile malnutrition: Changes in body composition during rehabilitation.

  Pediat. Res. 1969: 3:579-89
- 8. Linder, G.C., Hanse, J.D.L. and Karabus, C.D. (1963).
  The metabolism of magnesium and other inorganic cotions
  and of nitrogen in acute kwashiorkor. Pediatrics 1963; 31:552-68
- 9. Mann, M.D., Bowie, M.D. and Hansen, J.D.L. Total body potassium and serum electrolyte concentrations in protein energy malnutrition 1975; 49:76-8
- 10. Mata, L.J., Jimenez, F. Crodon, M. Rosales, R., Prera, E., Schneider, R.E. and Viteri, F. Gastrointestinal flesa of children with protein colonic malnutrition. Am. J. Clin. Nutr. 1972; 25: 1118-26.
- Viteri, F.E. and Schneider, R.E. Gastrointestinal alterations in protein - colonic malnutrition. Med. clins N. Am. 1974; 58: 1487-1505.
- 12. Waterlow, J.C. Golden M.H.N. and Patrick J.
  Protein Energy malnutrition: Treatment in Nutrition
  in the clinical Management of Disease (Eds). Dickerson W.T.,
  Lee, H.A. Edwards Arnold, London P.

- 13. Rees L. and Brook C.G.D. Gradual reintroduction of full-strength milk after acute gastroenteritis in children.
- 14. Alleyne G.A.O., Hay, P.W., Picon D.I., Stanfield J.P., and Whitehead R.G. The treatment of severe protein-energy malnutrition.
- 15. Molla A, Molla A.M. and M. Khahan
  Effect of nutritional status of children on intake and
  absorption of nutrients presented in symposiu sponsored by Dept.
  of pediatrics, University of Leuven. Belgium Oct. 1983.
- 16. Molla A, Molla A.M., Rahim A, Sarker S.A., Mozafar Z, Rahaman M.M. Intake and absorption of nutrients in children with cholera and rotavirus infection during acute diarrhoea and after recovery. Nutr. Res. 1982; 2:233-42
- 17. Molla A, Molla A.M., Sanker S.A., Khetoch M, M.M. Rahaman Effects of acute diarrhoea on absorption of macronutrients during disease and after recovery. IN Diarrhoea and Malnutrition. Eds. L.C. Chen and N.S. Scrimshaw. Plenum publishing corporation, 1983: 143-53
- 18. Molla, A.M., Molla A, Sarker S.A. and M.M. Rahaman Food Intake during and after Recovery from Diarrhoea in Children. In Diarrhoea and Malnutrition Eds. L.C. Chen and N.S. Scrimshaw. Plenum Publishing Corporation 1983; 113-23,
- 19. Molla A, Molla, A.M., Sarker S.A. and M. Khatum. Whole gut transit time and its relationship to absorption of macronutrients during diarrhoea and after recovery.

  Scand J. Gastro. 1983; 18:537-43
- 20. Henry, R.J. Clinical chemistry: Principles and Technics. Harper and Rwo New York, 1964
- 21. Van de Kamer, J.H., Ten Bokkel Huiniuk, H and Weyers, H.A.
  Rapid method of determination of fat in feces. J. Biol. Chem.
  1949; 177-507-12
- 22. Roe J.H. and Rice E.W. Photometric method of determination of free pentoses in animal tissues. J. Biol. Chem. 1948; 173;507-12

## SECTION III - BUDGET

## A. Detailed Budget

## 1. Personnel Services:

<u>Name</u>	Position & Annual Salary	% Effect	Project Re Tk.	quirement US \$
Dr. Ayesha Molla	Assoc.Scientist Tk (494100.00)	25% 1 yr	123525.00	
Dr. A.M. Molla	Scientist \$ (63741.00)	10% l yr	_	6,374.10
One physician ICDDR,B	(Gr.6 Step 1) Tk (76,376.00)	20% l yr	15275.20	
One physician CNU	-	15% l yr	-	-
Dr. Sultana CNU	Medical Director	10% l yr	-	
Mrs. N. Majid	Dietician Tk (64,608.00)	20% l yr	12921.00	
Ms. M. Khatun	Res.Officer Tk (77,229.00)	20% l yr	15445.80	-
One Study Clerk	Tk.33,786.00	20% l yr	6757.20	-
Four cleaners	Tk.116,124.00	25% 1 yr	29031.00	_
	Sub Total :		202955.20	6,374.10
2. Supplies and Mate	erials:			
Stationery Goods			2000.00	-
Xeroxing and mimeogra	aphing		2500.00	
Medical illustrations	5		1500.00	
PUC bags		•	-	300.00
Miscellaneous (including vitamins, medicines)	minerals and		4000.00	-
medicines)			10,000.00	300.00

3. Equipment:		None .	
4. Laboratory Tests:			Tk. \$
Blood test (TC, DC, HCT			1000 00
	Tk. 15 x 80		1200.00 -
Albumin (nu.80)	\$ 1.55 x 80		2480.00 - 1600.00 -
X-ray (nu 40)	Tk. 40 x 40	•	15200.00 -
Kjeldahl N <sub>2</sub>	\$7.6 x 100		
Fecel Fat	\$41 x 100		82000.00 -
Xylose	\$4.3 x 80		6880.00 -
Calorific value	\$ 5 x 100		10000.00 -
Serum electrolytes	\$ 2 x 40`		1600.00 -
Blood culture	Tk. 22 x 40.		660.00 -
Urine culture	Tk. 14 x 40		560.00 <del>-</del>
Stool culture for all			700 00
plates	Tk 15 x 40		700.00 -
Stool M/E	Tk. $2.55 \times 40$		102.00 -
Rotavirus assay	Tk 15 x 40		600.00 -
		Sub total T	k.127966.00 -
5. Transportation of I	Patients:		
	Tk 15 x 1500	=	22,500.00 -
6. Patient Hospitaliza	ation		
	Tk. 200 x 80 x 28	=	4,48000.00
			·
		m. 01	1421.20 \$ 6404.10
	Total	$= TK \cdot 81$	1421.20 \$ 6404.10
		= \$ 32,	,456.84
	Grand Total	=	\$ 38860.84
	Incremental lost		\$ 24,368.00

## BUDGET SUMMARY

1.	Personnel •	TK	<u>\$</u>
		2.02955.20	6374.10
2.	Supplies & Materials	10,000.00	300.00
3.	Equipment	-	<u></u>
4.	Laboratory tests	1,27966.00	-
5.	Transportation	22.500.00	-
6.	Patient Hospitalizatio	n 4,48000.00	_
	Total	8,11421.20	6404.10
	Grand Total in	\$ 38,860.84	
	Incremental Cost	\$ 24,368.00	

Table 1.

## MILK FORMULAE USED IN UGANDA AND JAMAICA (14)

Uganda (100 kcals,2.8 gm protein in each 100 ml)		Jamaica (135 kcal,3.14 gm protein in each 100 ml)	
Dried Skimmed Milk Powder	789 gm	Full Cream Milk	<del></del>
Cotton Seed Oil	59 gm	plus added carbohydrate (Pelargon)	190 gm
Sucrose	47 gm	Arachid oil	55 gm
Kc1	1.0 gm		
Mg (OH) 2	0.5 gm		
Ma	de in 1 litre	<del></del> Mad	e in   litre

Table 2
DIETARY REGIMEN AT THE CNU, ESKATON

Food item	Marasmus	Marasmus- kwashiorhor	Kwashiorkor
Dried skim milk (DSM) given 2 hourly for 24 hrs using cup or spoon	150 ml/kg/day initially then increased up to 250 - 300 ml/kg/day	100 ml≮kg/day	100 ml/kg/day
4 types of cooked solid meal (without salt). Offered from the 1st day of admission at 8 am, 12 noon 3 pm & 6 pm	Offered	Offered	Offered
	ad libitum	ad libitum	ad libitum
3 types of cooked meal (breakfast, lunch, & supper) & 4 milk feeds (6am, 10am, 4pm & 10pm) given at the beginning of the 2nd week	Offered	Offered	Offered
	ad libitum	ad libitum	ad libitum

Table 3

## FULL STRENGTH DSM (CNU)

DSM	-	80 gm
Vegetable Oil	_	30 gm
Glucose	_	67.5 gm
Made .upto	-	l litre

828 calories/litre

## RICE PUDDING

		Kcal	Protein (gm)
Rice 900 gm	<u></u>	3105	61.2
Sugar 200 gm	-	800	0
Milk 200 gm	-	714 .	76.0
After Cooking		68 Kcal %	1.94 gm %

## RICE-MEAT-VEGETABLE

		Kcal	Protein (gm)
Rice 1200 gm	***	4152	76.8
Pumpkin 2000 gm	_	520	20.0
Meat 1200 gm	-	1368	271.2
Onion 10 gm	-	6	0.18
Oil 38 gm	-	270 .	0
After cooking		80 cals %	4.3 gm %

## Table 3 (cont.)

## RICE-DAL

		<u>Kcal</u>	Protein (gm)
Rice 1000 gm	-	3460	64.0
Dal 700 gm	-	2401	175.7
Onion 10 gm	-	6	0.18
Spices 5 gm		0.9	0.05
After cooking		77 cals %	2.9 gm %

## SNACK ROLL

	Kcal	Protein (gm)
Atta (wheat flour) 400 gm-	1384	42
Sugar 40 gm -	160	0
Oil !0 gm -	90	0
Yeast 2 gm -	5	0.74

Table 4 . SELECTION OF STUDY PATIENTS, WHO WILL BE GIVEN TWO EXPERIMENTAL DIETS

Particulars	Low Fat Diet (30%)	High Fat Diet (48%)
Age (yrs)	1 ½-3	1 ½ -3
Grades of Malnutrition wt. for ht. and number of patients		
(a) (80-60% with oedema kwashiorhor/m. kwashiorkor	10	10
(b) 60% No oedema	10	10

Table 5.

LOW FAT DIET AND THE FEEDING SCHEDULES FOR THE BALANCE STUDY OF SEVERE PEM PATIENTS (Age 1½ yr to 3 yr)

Energy required 1300 kcal Extra for wt gain - 500 "

	Cooked	Ingredients	Nutrient Contents			
Time	Food	(gm)		Prot (gm)	Fat (gm)	Kcal
7 am	Halua	Rice Powder	35	11.27	10.35	628
10 am		Dano Sugar Veg. Oil Water	35 60 10 225			
10 am	Mild	Dano Rice Powder Sugar Veg. Oil Water	16 5 10 200		6.27	158
12 noon	Rice Curry	Rice Chicken Onion Veg. Oil	50 60 20 12	15.54	12.0	173 183
3 pm	Milk	as above		4.51	6.27	158
6 pm	Rice	as above		18.74	12.0	356
9 pm	Milk	as above		4.51	6.27	158
				62.28 13.7% of calories	62.16 30% of calories	1814

<sup>\*</sup> The solid diet of this Table will be prepared packaged in polythene bags, supplied twice weekly to CNU. These will be stored in  $-20^{\circ}$ C and warmed to make it soft before feeding.

Table 6.

\*\*
HIGH FAT DIET AND THE FEEDING SCHEDULES FOR THE BALANCE STUDY
OF SEVERE PEM PATIENTS (Age 1½ yr to 3 yrs)

Energy Required - 1300 kcal Extra for wt gain - 500 kcal

	Cooked	Ingredients			ient Contents	
Time	Food	(gm)		Prot (gm)	Fat (gm)	Kcal
7 am	Halua	Rice Powder	25	8.05	38.67	576
		Dano · • Sugar	25 35			
		Veg. Oil	25			
		Water	175			
10 am	Mi1k	Dano	16	4.38	9.27	162
		Rice Powder	4			
		Sugar	6			
		Veg. Oil	. 5			
		Water	200			
12 noon	Rice	Rice	35	2.24	8.0	193
12 110011	RICC	Veg. Oil	8			
	Curry	Chicken	60	15.54	12.0	183
	•	Onion	20	•		
		Veg. Oil	12			
2	Milk	as above		4.38	9.27	162
3 pm	mir	as above		1100	<b>,</b> ,	
6 pm	Rice &	as above		17.78	20.0	376
•	Curry	as above		17.70	20.0	370
					0.07	162
9 pm	Milk	as above		4.38	9.27	162
				56.8	99.5	1814
			•	of total	(50% of total	≣
•			ca	alories)	calories)	
-						

<sup>\*</sup> The solid diet of this Table will be prepared packaged in polythene bags, supplied twice weekly to CNU. These will be stored in -20°C and warmed to make it soft before feeding.

Table 7.

# TWO HOURLY FEEDING SCHEDULE FOR THE FIRST 3 DAYS OF HOSPITALIZATION (100 TO 150 KCAL/KG/DAY) FOR A 8 KG CHILD

Tir	ne	Coocked Food	Quantity (gm)	<u>Kcal</u>
6	am	* Halua ·	50-100	90-180
8	am	Khichuri ·	50-100	140-280
10	am	Milk	80-100	64-100
12	noon	Khichuri**	50-100	50-100
2	pm	Halua	50-100	90-180
4	pm	Khichuri	50-100	50-100
6	pm	Milk	80-100	64-100
8	pm	Halua	50-100	90-180
10	pm	Khichuri	50-100	50-100
12	midnight	Milk	80-100	64-100
2	am	Milk	80-100	64-100
4	am	Milk	80-100	64-100
			750-1200 gm	880-1620

## All feeds will be given ad libitum

\* Halua : See the preparation in Table 5.

\*\* Khichuri: Rice 80 gm, lentil 20 gm, chicken 30 gm, potato 25 gm, onion 25 gm, oil-20 ml.

Nutrient content prot. - 2.6 gm%, fat 2.9 gm%, Energy 100 kcal%.

#### CONSENT FORM

International Centre for Diarrhoeal Disease Research is carrying out studies to find out the impact of diarrhoea due to different casuses on absorption of nutrients in children. Similar studies were done on cholera, rotavirus, ETEC, Shigella and in diarrhoea due to Giardiasis. Now we intend to carry out a study on severely malnourished children to investigate the quantity of food intake pattern and absorption of nutrients during early and late phase of rehabilitation. of your child is between 12 and 3 years, severely underweight compared to normal (marasmic) and has oedema (kwashiorkor) will be admitted in During the first three to four days of hospitalization, the study. all sorts of infection will be diagnosed and treated. During this time 3 to 5 cc of blood will be taken for diagnostic purposes. children will be fed milk formula in every two hour and if necessary, will be fed by using nasogastric tube. After that, a 72 hour balance During this time babies will be fed, Milk, Halua, study will be done. Rice, Chicken Curry etc. six times a day. Quantity of intake and output will be recorded and food, urine and stool will be analyzed in the laboratory. Before going home, another 72 hour balance study.will be done in a similar way. To monitor the improvement of your child, 2 c.c. blood will be taken at this time for laboraotry investigation. For assessment of absorption status, xylose test will be done two times during early and late phase of rehabilitation. For this purpose, a total of 1 c.c. blood (0.5 c.c. each time) will be taken. For complete recovery, your child would need to stay in the hospital for 3 to 4 weeks and during this time one guardian should stay with the child in the hospital.

Entirely it depends upon your decision if you would like to participate in this study or not. However, if you decide not to participate, usual treatment for child\_will be provided. please give your signature if you decide to participate.

Signature of the	Investigator
------------------	--------------

Fingerprint/Signature of the Guardian

Date			

my mars grave moral wer sensone justicus nears NOIRE . SOSL DN- CM. MERLER RESTLER SHE SLESS SUBSRY, PANUER 1 Er zuen - g - reusi. Kersissississis - reus 73. Experience of the second of th Libertyrani- 5 37 milite sureme 3850 milita reservent 7 20121- 1020. 2120 - 100 M 1 JULETES 32020- SIN 5 JU ur late pous muss. olt sur 13.) 384 missig. (Wille 7) ( Lee 1826 ' N3J - SI 2021. ( Maranum) St. br 3201922. That size ( xmry - 2002, 2002, - 75 161 - 22/28. 5/3 - Mearen 1 - 12/30-37 - 6/3, 52/20 - 104 Cahre. Pashir. whyed. geolophis- mags (12- causes- legesm)-331. 512 73.) Resselvezone 22, per-conse. @ word 3.33 JMDN-(UN 212-1 JMDN- MN BEGAR- DAB- PM(4-25 413-ENPROS. PZ. (W3/2 5/2. " NOPZ. S/(R. (ND) IL DEN (R. GO) (335- WOW). 94 PACH - N3MUL 512 1 MISINDO. 12RM24 maria. 862 20 30 30222 lauplese. 842. 1 731/2 65 mores. 201004 man- avolene sedne 124 es. 126. es. 1310 sep. - 251013 & 2200-(AUR. 2,1/220- 122/26-5/2 5/2 1 EUPONTE, 2232222 5/32 were sul vassistan mosition (post con 5/2 3/2 Mansteri sola suela sala sistata so siri sar-lan OBSKARS WRE 3- 1932) SLAS 5 12 1 2000 45 MM. 85 MACA 1297 SURVE, MISALS, SURSULL, SLAR SAD, I SUDA word. 75% the white 5 dut sine 500 destarget WYB21. SIME. 89-1 West Tracedo- MSD 3 M. JRES SIEN PULO- 1012 5/2 1 20020 - MSCHOLD P, TUD. more - 80) James 2 min 335 (43 Vr 2 18-1

Pagler like. Minchi. masse. rang 1 2002- perezusi. Masolux Jun. 5124-1 322. Ule. Zw. - Lazs. Lali- 1 32.21 20 lule. Pagles 3 muses. -J sulsoun. Jose (vis see cons marly sunces. 700.

mar

2/222/10 - 12882 - EX PRESENTS

72820(13- M2320-